B+
Bull case
25%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
BEAM
Beam TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The September BEAM-302 biomarker update and pivotal-cohort start support a cautiously positive development thesis. Risto-cel and BEAM-301 offer distinct 2026 milestones, while Beam reported $1.153 billion of cash, equivalents and marketable securities at June 30, 2026 [#IR-2026-09-08][#SEC-8K-2026-08-04].
Posture
Defensive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-10-29.
What can break
Beam reported a $122.7 million second-quarter net loss; its stated runway into mid-2029 assumes, among other things, an expected additional $200 million draw under its Sixth Street facility [#SEC-8K-2026-08-04].
Momentum
41
Value
41
Sentiment
61
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $29.00 · Bull $43.00 · Bear $13.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-29 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-29
Investment thesis
As of 2026-10-29
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-29. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $48.50
Why
Momentum41 · Δ7d +19.7
Value41 · Δ7d -0.1
Sentiment61 · Δ7d -14.9
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 2 setup hits (3d) with net bullish as of 2026-10-29.
- • Sentiment remains the lead driver in the composite, 7D delta -14.9.
Contradictions & invalidation
- • Beam reported a $122.7 million second-quarter net loss; its stated runway into mid-2029 assumes, among other things, an expected additional $200 million draw under its Sixth Street facility [#SEC-8K-2026-08-04].
- • Beam's September trade-secret lawsuit creates legal cost and intellectual-property uncertainty. The claims are allegations, not established misconduct or evidence of clinical-program performance. Docket: https://dockets.justia.com/docket/massachusetts/madce/1%3A2026cv14414/306818
- • BEAM-302's interim biomarkers are not proof of clinical benefit or an accepted accelerated-approval package.
Catalyst clock
2026-12-31
Risto-cel data and potential BLA submission
Lead driver: Sentiment · See AI snapshot
Momentum
41
8% active weight
Current posture
7d trendImproving
Δ7d
+19.7
Δ21d
+27.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
61
45% active weight
Current posture
7d trendSoftening
Δ7d
-14.9
Δ21d
-20.3
Why this grade
Composite grade D. Momentum 40.6 / Value 40.7 / Sentiment 60.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$29.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$2.98B
Beta
2.12
Shares Out
103.29M
P/E (TTM) · Derived
-35.7
P/S (TTM)
48.90
P/FCF (TTM) · Derived
-8.02
Rev YoY
-94.2%
EPS YoY
+17.4%
Gross Margin
+85.7%
Op Margin
-242.3%
Net Debt
-$1.09B
Current Ratio
14.57
As of 2026-10-29 • Updated nightlySource: Internal modelMethods & Data